This slide show presents tricks for surviving and thriving at the ASCO Annual Meeting in Chicago. Everything from transportation, McCormick Place, planning your days, using social media, which sessions to attend, how to network, where to eat, and how to be a tourist in Chicago.
Most metastatic cancer patients are still receiving aggressive methods of treatment near the end of life, and palliative/supportive measures are significantly underutilized.
I hope to see many of the exciting agents presented this year become available and affordable for my patients. But when the miracle isn’t happening we have an obligation to talk it out and be candidly compassionate. We need to know when to put the pedal to the metal and when to hit the brake.
I am inspired to finally see the increasing role of immuno-oncology agents in the treatment of cancer, and ASCO 2016 was loaded with fascinating updates on this subject.
To date, there is still no strong evidence that induction chemotherapy improves outcomes for locally advanced head and neck cancer.
This one-act play features a patient, former smoker, navigating the CMS rules for lung cancer CT screening in a shared decision-making session with his doctor.
Throughout the geriatric sessions we were continually reminded of our aging population, the fact that cancer is a disease of the aging, and of the mismatch in this increasing number of patients and the number of geriatric providers entering the workforce. General oncologists will need to understand the nuances of caring for older patients with cancer.
The landscape of cancer therapy is shifting from traditional cytotoxic chemotherapy towards targeted therapy with agents like tyrosine kinase inhibitors and monoclonal antibodies. However, these newer agents remain costly, and traditional chemotherapy remains the backbone for treating most malignancies.
Several factors affect physicians’ choice of genomic tests, including availability, speed, and cost. Traditionally allelotyping have been used, since they are fast and sensitive, even though they are not comprehensive.
Words like value, quality, and even cost flowed freely at the ASCO Annual Meeting this year. Along with great excitement about the latest and greatest ways to understand tumor biology and treat cancer patients, there is an increasing recognition that we need to consider whether the things we do are worth it.